Q1 Earnings Estimate for CRNX Issued By Lifesci Capital

Key Points

• Lifesci Capital forecasts Q1 2026 EPS of ($1.33) and FY2026 EPS of ($5.35) for Crinetics and assigns the stock a Strong-Buy rating.
• Crinetics last reported EPS of ($1.29), beating consensus of ($1.37) and posting revenue of $6.16M versus $4.32M estimates, but the company remains deeply unprofitable with a reported negative net margin of 6,046.22%.
• Analyst views are mixed but the average price target is $76.75 versus the current share price around $38.15, while insiders sold about $5.57M of stock in the past three months and institutions own 98.51%.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Research analysts at Lifesci Capital issued their Q1 2026 earnings estimates for Crinetics Pharmaceuticals in a research note issued to investors on Tuesday, April 28th. Lifesci Capital analyst K. Dellorusso forecasts that the company will post earnings per share of ($1.33) for the quarter. Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Crinetics Pharmaceuticals' current full-year earnings is ($4.90) per share. Lifesci Capital also issued estimates for Crinetics Pharmaceuticals' Q2 2026 earnings at ($1.34) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($1.35) EPS and FY2026 earnings at ($5.35) EPS.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($1.29) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $0.08. The firm had revenue of $6.16 million during the quarter, compared to analyst estimates of $4.32 million. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 41.46%. The company's quarterly revenue was up NaN% on a year-over-year basis. During the same quarter last year, the business earned ($0.88) earnings per share.

A number of other equities analysts have also weighed in on the stock. Wall Street Zen lowered shares of Crinetics Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $67.00 target price for the company in a research report on Monday, January 12th. Morgan Stanley increased their target price on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a research report on Monday, April 20th. Finally, Citizens Jmp raised their price objective on shares of Crinetics Pharmaceuticals from $96.00 to $97.00 and gave the company a "market outperform" rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Crinetics Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $76.75.

Crinetics Pharmaceuticals Stock Down 1.2%

Shares of NASDAQ:CRNX opened at $38.15 on Wednesday. The firm has a market capitalization of $3.99 billion, a PE ratio of -7.72 and a beta of 0.30. Crinetics Pharmaceuticals has a twelve month low of $25.83 and a twelve month high of $57.99. The company has a 50-day moving average price of $38.72 and a two-hundred day moving average price of $43.99.

Insider Buying and Selling

In other news, insider Stephen F. Betz sold 10,612 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $37.37, for a total value of $396,570.44. Following the completion of the transaction, the insider directly owned 137,101 shares in the company, valued at approximately $5,123,464.37. This trade represents a 7.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Richard Scott Struthers sold 21,981 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $821,429.97. Following the completion of the transaction, the chief executive officer owned 404,778 shares of the company's stock, valued at $15,126,553.86. This trade represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 142,380 shares of company stock valued at $5,569,475 in the last three months. Insiders own 6.00% of the company's stock.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

A number of large investors have recently modified their holdings of CRNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Crinetics Pharmaceuticals by 11.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company's stock valued at $1,995,000 after acquiring an additional 6,148 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Crinetics Pharmaceuticals by 6.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company's stock valued at $11,658,000 after purchasing an additional 22,305 shares in the last quarter. Strs Ohio purchased a new stake in Crinetics Pharmaceuticals in the first quarter valued at approximately $124,000. Invesco Ltd. raised its stake in Crinetics Pharmaceuticals by 11.7% in the second quarter. Invesco Ltd. now owns 78,140 shares of the company's stock valued at $2,247,000 after purchasing an additional 8,181 shares in the last quarter. Finally, Sei Investments Co. raised its stake in Crinetics Pharmaceuticals by 20.6% in the second quarter. Sei Investments Co. now owns 60,180 shares of the company's stock valued at $1,731,000 after purchasing an additional 10,269 shares in the last quarter. 98.51% of the stock is currently owned by institutional investors.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.